Quantitative Biology Seminar
Add to your list(s)
Download to your calendar using vCal
If you have a question about this talk, please contact .
Many cancers are driven by hyperactive point mutants, most of which remain undruggable by the conventional approach with small molecule drugs. I will discuss biologics-based strategies to effectively target mutated cancer drivers, including the development of biologics that are exquisitely selective to cancer driver mutants and the use of covalent inhibitors to create actionable neoantigens for immune therapy.
This talk is part of the Seminars on Quantitative Biology @ CRUK Cambridge Institute series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
|